Vinita Kailasanath drafts and negotiates contracts for the commercialization and protection of intellectual property and technology, and advises clients on issues at the intersection of intellectual property and FDA regulation.

Ms. Kailasanath assists leading life sciences companies and technology solutions providers with license agreements, master services agreements, supply agreements, clinical trial agreements, software as service arrangements, terms of use, privacy policies, sweepstakes and contest rules, consulting agreements, and confidentiality agreements among others. Additionally, she counsels clients regarding citizen petitions to FDA, Form FDA 3542a submissions, Bayh-Dole related issues (including US manufacturing waiver requests), Orange Book listing, and BPCIA-related matters.

Ms. Kailasanath advises technology clients on patent and licensing law, reexaminations, responses to data breaches, and the intellectual property and technology licensing aspects of mergers and acquisitions. She also counsels clients on the legal aspects of museums and art.

Ms. Kailasanath served as Editor-in-Chief of the Stanford Technology Law Review. She has also worked in the legal department of a leading alternative energy company specializing in the production of algal oils and bioproducts.

Prior to attending law school, Ms. Kailasanath conducted graduate-level neuroendocrinology research and co-authored several publications. She also worked as a life sciences marketing and sales management consultant.


  • Subsidiary of a Fortune 100 company with a series of technology and services contracts, including platform creation, SaaS and service level agreements, to create and launch a novel service.
  • Specialty pharmaceutical company in connection with research and development, licensing, regulatory and litigation matters.
  • US medical instrument and supply company with a license and supply agreement.
  • Various clients on website best practices and e-commerce issues including website terms of use, privacy policy, and click-wrap end user license agreements.
  • Online content, products, and services company with advice regarding the intellectual property and technology licensing aspects of mergers and acquisitions.

  • Biotechnology center with a master services agreement with a contract research organization.
  • Drug development company with a clinical supply agreement.
  • Biotechnology company developing therapies based on gene delivery technology with amendments to a series of license agreements and an evaluation, feasibility and option agreement.
  • Medical device company in connection with the drafting and negotiation of numerous consulting, supply and development agreements with universities, development and supply partners around the world.


Life Science Transactions: Getting to a Successful Deal
Arnold & Porter Seminar, Cambridge, MA
ANDA, 505(b)(2) Applications and Patent and Exclusivity Issues at Introduction to US Drug Law and Regulation
Food and Drug Law Institute (FDLI), South San Francisco, CA
Joint Development Agreements – Best Practices for Partnering
Speaker, ACC- SFBA Patent Law Committee Program, Silicon Valley and San Francisco, CA
Social Media: Navigating the Legal Issues
Arnold & Porter Webinar
Social Media Training for Nonprofits: Navigating the Legal Issues
Arnold & Porter Insights for Nonprofit Organizations Breakfast Series, Washington, DC


Northern California Super Lawyers
"Rising Star" (2018)


  • JD, Stanford Law School, 2010
  • MS, Biological Sciences, Stanford University, 2004
  • BA, Human Biology, Stanford University, 2004, with honors and distinction, Phi Beta Kappa
  • California
  • District of Columbia
  • US Court of Appeals for the Federal Circuit
  • United States Court of Appeals, Federal Circuit, The Honorable Arthur J. Gajarsa
  • Member, Licensing Executive Society
  • Member, Food and Drug Law Institute

Email Disclaimer